Table 6. Mental and neurological outcomes for individual drugs by malaria treatment studies.
-No observations.
| Drug | Psychiatric/
behavioural |
Mild
neurological perturbations |
Motor
problems |
Sleep pattern
disturbances |
Personality
changes |
Seizures | Headache | Hearing &
balance problems |
Visual
problems |
Cognition
problems |
|---|---|---|---|---|---|---|---|---|---|---|
|
Mefloquine,
N=6293 (%) |
2 (0.03) | 136 (2.16) | 40 (0.64) | 114 (1.81) | 1 (0.02) | 1 (0.02) | - | - | - | - |
|
Chloroquine,
N=189 (%) |
2 (1.06) | 14 (7.41) | - | - | 1 (0.53) | 1 (0.53) | - | - | - | - |
|
Sulfadoxine,
N=340 (%) |
2 (0.59) | 9 (2.65) | - | - | - | - | 1 (0.29) | - | - | - |
|
Pyrimethamine,
N=340 (%) |
2 (0.59) | 9 (2.65) | - | - | - | - | 1 (0.29) | - | - | - |
|
Artemether,
N=6332 (%) |
- | 123 (1.94) | 40 (0.63) | 114 (1.80) | - | - | - | 150 (2.37) | - | - |
|
Artesunate,
N=6282 (%) |
- | 136 (2.16) | 40 (0.64) | 114 (1.81) | - | - | 16 (0.25) | 8 (0.13) | 1 (0.02) | - |
|
Quinine, N=263
(%) |
- | 8 (3.04) | 10 (3.80) | - | - | 5 (1.90) | 16 (6.08) | 34 (12.93) | 1 (0.38) | - |
|
Lumefantrine,
N=1144 (%) |
- | 123 (10.75) | 40 (3.50) | 114 (9.97) | - | - | - | 150
(13.11) |
- | - |
|
Amodiaquine,
N=227 (%) |
- | - | - | - | - | - | - | - | - | - |